Unicycive Therapeutics, Inc..
Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications
- Reports this week
- 1
- Active events
- 0
- Connections
- 20
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Unicycive Therapeutics, Inc. this week
News at the entities that move Unicycive Therapeutics, Inc. most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Unicycive Therapeutics, Inc.
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Unicycive Therapeutics, Inc.
-
Benchmark TransactionalMarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.Moves Unicycive Therapeutics, Inc.
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves Unicycive Therapeutics, Inc.
-
company Shared contextBoard approved a quarterly cash dividend increase on August 1, 2026.Moves Unicycive Therapeutics, Inc.
-
LinkedIn Shared contextBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Unicycive Therapeutics, Inc.
Connections
The 14 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Unicycive Therapeutics is undergoing formal drug development review by the FDA, culminating in multiple Complete Response Letters regarding compliance issues.
-
Shalabh Gupta Structural
Shalabh Gupta serves as the Chief Executive Officer and holds a 5.0% ownership stake in Unicycive Therapeutics, Inc.
-
Nasdaq Structural
Unicycive Therapeutics is formally listed and trades on the Nasdaq stock exchange.
-
John Townsend Structural
John Townsend served as the Chief Financial Officer of Unicycive Therapeutics, Inc.
-
Benchmark Transactional
Benchmark provides financial research reports and price objectives regarding Unicycive's shares.
-
LinkedIn Shared context
Unicycive Therapeutics utilizes LinkedIn as a platform for professional presence, investor outreach, and public communication.
-
DGF Operational
Unicycive Therapeutics is actively developing treatments aimed at preventing DGF.
-
National Kidney Foundation Mentioned together
Unicycive Therapeutics presented clinical data at National Kidney Foundation meetings.
Show all 14 connections
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data for Unicycive Therapeutics, Inc.
-
American Nephrology Nurses Association Mentioned together
Unicycive Therapeutics presented research data at the American Nephrology Nurses Association symposium.
-
company Shared context
A lawsuit alleges that Unicycive made misleading statements regarding its status as a company.
-
Brookline Mentioned together
A financial entity named Brookline Capital Markets was mentioned in connection with the entities.
-
New York Shared context
Unicycive Therapeutics, Inc. is headquartered in New York.
-
ODD Mentioned together
No direct relationship between ODD and Unicycive Therapeutics, Inc. was observed in the provided evidence.